Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kotra Industries Berhad (0002.KL)
Malacca, MY
Kotra Industries Berhad operates as an investment holding company, primarily involved in the development, manufacturing, and distribution of pharmaceutical and healthcare products throughout Malaysia. The firm provides a range of nutraceuticals, including health supplements under its Appeton brand, specifically designed for children, expectant mothers, and the elderly. Its extensive pharmaceutical portfolio features the Axcel brand, which covers pediatric care, anti-infective treatments, gastroenterology, and dermatology. Additionally, the company supplies sterile antibiotic injectables via its Vaxcel brand, asthma control products through Arite, treatments for fungal infections under the Creobic brand, and hair loss prevention items with the Minox brand. Furthermore, its AxPain brand offers solutions for various pain conditions, such as headaches, migraines, backaches, toothaches, aches from colds and flu, muscular rheumatism, menstrual discomfort, and fever. Founded in 1982, Kotra Industries Berhad is headquartered in Malacca, Malaysia, and functions as a subsidiary of Piong Nam Kim Holdings Sdn. Bhd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.80% | -4.50% | -4.74% | -7.95% | -9.05% | -7.95% | -9.05% | -30.16% | +55.92% | +274.51% | +415.58% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | +1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+1.9% Q1'26: -10.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-3.3% Q1'26: -32.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+21.0% Q1'26: -12.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+22.3% ★ Q1'26: +22.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+18.3% ★ Q1'26: +12.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.04× ★ Q1'26: 0.40× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
172.55M
est: 189.70M (-9.0%)
|
171.73M
est: 189.70M (-9.5%)
|
159.62M
est: 199.40M (-19.9%)
|
242.20M
est: 246.37M (-1.7%)
|
226.55M
est: 244.63M (-7.4%)
|
230.78M
est: 248.80M (-7.2%)
|
275.10M
275.10M – 275.10M
+10.6% YoY
|
284.50M
284.50M – 284.50M
+3.4% YoY
|
| EBITDA |
37.74M
est: 58.84M (-35.9%)
|
43.50M
est: 58.84M (-26.1%)
|
43.03M
est: 61.85M (-30.4%)
|
80.89M
est: 76.41M (+5.9%)
|
70.78M
est: 75.88M (-6.7%)
|
64.99M
est: 77.17M (-15.8%)
|
85.33M
85.33M – 85.33M
+10.6% YoY
|
88.24M
88.24M – 88.24M
+3.4% YoY
|
| EBIT |
23.77M
est: 45.46M (-47.7%)
|
27.54M
est: 45.46M (-39.4%)
|
27.15M
est: 47.79M (-43.2%)
|
66.27M
est: 59.04M (+12.2%)
|
56.51M
est: 62.45M (-9.5%)
|
51.38M
est: 63.51M (-19.1%)
|
70.23M
70.23M – 70.23M
+10.6% YoY
|
72.63M
72.63M – 72.63M
+3.4% YoY
|
| Net Income |
22.20M
|
29.56M
|
24.39M
|
65.23M
est: 67.68M (-3.6%)
|
44.60M
est: 48.20M (-7.5%)
|
42.48M
est: 45.09M (-5.8%)
|
48.20M
48.20M – 48.20M
+6.9% YoY
|
49.54M
49.54M – 49.54M
+2.8% YoY
|
| SGA |
30.00M
est: 19.79M (+51.6%)
|
30.41M
est: 19.79M (+53.7%)
|
22.68M
est: 20.80M (+9.0%)
|
31.23M
est: 25.70M (+21.5%)
|
28.84M
est: 25.51M (+13.0%)
|
—
est: 25.95M (-100.0%)
|
28.69M
28.69M – 28.69M
+10.6% YoY
|
29.67M
29.67M – 29.67M
+3.4% YoY
|
| EPS |
0.16
|
0.20
|
0.17
|
0.44
est: 0.46 (-3.6%)
|
0.30
est: 0.33 (-7.7%)
|
0.29
est: 0.30 (-4.6%)
|
0.33
0.33 – 0.33
+6.9% YoY
|
0.33
0.33 – 0.33
+2.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Teck Onn Piong | MD & Director | 4.8K | male |
| Chong Liang Chua | Chief Financial Officer | — | male |
| Ley-Theng Tan | Joint Secretary | — | — |
| Ming Loong Cheah | Chief Operating Officer | — | male |
| Siew Chuan Chua FCIS MAICSA | Joint Secretary | — | female |
| Swee Chang Chin | Chief Information Officer & Executive Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0002.KL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
